BioReference Laboratories

BioReference Laboratories
Name	BioReference Laboratories
Type	Subsidiary
Industry	Clinical laboratory
Founded	1981
Headquarters	Elmwood Park, New Jersey, United States
Key people	George Chamoun, Jon Cohen (physician), Ramin Koukash
Products	Clinical testing, molecular diagnostics, pathology services
Parent	OPKO Health

BioReference Laboratories is a large American clinical laboratory company providing diagnostic testing, molecular services, and anatomic pathology to hospitals, physicians, and consumers. Founded in 1981, it expanded through regional acquisitions and strategic partnerships to become a prominent reference laboratory with national reach. The company played a significant role during public health responses and has been involved in corporate transactions and regulatory scrutiny.

History

BioReference Laboratories was established in 1981 amid growth in commercial laboratory services and the rise of molecular diagnostic techniques, competing with firms such as Quest Diagnostics, Laboratory Corporation of America Holdings, and ARUP Laboratories. Early expansion included pathology acquisitions and collaborations with regional health systems like Hackensack University Medical Center and Mount Sinai Health System. In the 2000s and 2010s the company pursued roll-up strategies, acquiring regional laboratories and integrating technologies from firms linked to Molecular Diagnostics innovators and entrepreneurs associated with the biotechnology hubs of New Jersey and New York City. A major corporate event occurred when OPKO Health announced acquisition agreements, placing the laboratory within a portfolio alongside other diagnostics businesses tied to executives with prior affiliations to Turing Pharmaceuticals and investors active in healthcare private equity. During the 2020s, the laboratory scaled up testing capacity in response to the COVID-19 pandemic, partnering with academic centers and commercial logistics providers to manage surge demand.

Services and Testing

The laboratory offers a broad test menu spanning chemistry, hematology, immunology, microbiology, molecular oncology, and genetic testing, similar in scope to services provided by Mayo Clinic Laboratories and academic centers like Johns Hopkins Hospital and Massachusetts General Hospital. Offerings include high-throughput nucleic acid amplification tests used in infectious disease outbreaks, companion diagnostics employed alongside therapies from companies such as Roche and Pfizer (company), and women's health panels comparable to products from LabCorp. The pathology division delivers anatomic pathology reads and second-opinion consultations akin to collaborations seen with Memorial Sloan Kettering Cancer Center and Cleveland Clinic. The company also provided consumer-facing services through patient portals and retail partnerships resembling arrangements used by Walgreens Boots Alliance and CVS Health.

Facilities and Locations

Headquartered in Elmwood Park, New Jersey, the company operates multiple CLIA-certified laboratories and regional hubs across the United States, servicing metropolitan areas including New York City, Philadelphia, and Miami. Large capacity laboratories were developed to support surge testing capacity in response to public health crises, utilizing logistics frameworks similar to those of national distributors like United Parcel Service and FedEx. Clinical outreach included specimen collection sites, draw stations, and partnerships with hospital systems such as NYU Langone Health and Mount Sinai Health System to integrate laboratory services with inpatient and outpatient care. Research and development collaborations were conducted with academic institutions including Rutgers University and Columbia University.

Corporate Structure and Ownership

As a commercial laboratory entity, the company has undergone private ownership transitions, mergers, and acquisitions involving private equity and public corporations. Notable stakeholders and executives have had prior associations with healthcare investment firms and diagnostics companies such as OPKO Health, which completed a corporate transaction to acquire the business, bringing it under the same corporate umbrella as other life sciences assets tied to international investors and entrepreneurs with histories connected to Biotech ventures in Miami and international markets. Leadership and board composition have included executives with prior roles at diagnostics leaders like Quest Diagnostics and at hospital systems including Hackensack Meridian Health. Corporate financing rounds and strategic transactions mirrored patterns seen in deals involving Bain Capital and KKR in the healthcare sector.

Regulatory Compliance and Quality Assurance

The laboratory operates under federal and state regulatory frameworks, maintaining certifications and accreditations such as CLIA, CAP accreditation from the College of American Pathologists, and compliance with standards from the Clinical Laboratory Improvement Amendments and state departments of health in jurisdictions including New Jersey Department of Health and New York State Department of Health. Quality assurance programs include proficiency testing similar to schemes administered by the American Proficiency Institute and internal validation processes for molecular assays consistent with guidance issued by agencies like the Food and Drug Administration during emergency use authorizations. The company’s laboratory information systems interface with electronic health record vendors akin to Epic Systems and Cerner Corporation to support result reporting and data security frameworks paralleling standards from the Health Information Trust Alliance.

Controversies and Legal Matters

The company has faced legal and regulatory challenges typical of large clinical laboratories, including litigation and investigations concerning billing practices, reimbursement disputes with payers such as UnitedHealthcare and Aetna, and contract disagreements with health systems and commercial partners. During periods of rapid growth and during the COVID-19 pandemic, the laboratory contended with public scrutiny over test turnaround times and capacity constraints similar to controversies affecting other national laboratories. Antitrust and employment litigation arising from acquisitions mirrored cases seen in healthcare consolidation disputes adjudicated in federal courts such as the United States District Court for the District of New Jersey. Settlements and compliance agreements have been negotiated to resolve claims involving state regulators and private litigants.

Category:Medical laboratories Category:Companies based in New Jersey